New startup raises $50 million for cancer therapy
Avidicure has raised $50 million in an initial investment round. Its first product targets lung cancer.
Published on April 28, 2025
Team IO+ selects and features the most important news stories on innovation and technology, carefully curated by our editors.
Avidicure, a new biotechnology company, has raised $50 million in an initial investment round. The money will be used for an innovative antibody-based therapy. EQT Life Sciences led the round. The startup's first product targets lung cancer, among others.
The new startup from the Netherlands is developing so-called AVC Boosters. These are antibodies that strongly and specifically activate the immune system against cancer. They use the power of both the innate and acquired immune systems. The boosters combine the best properties of existing treatments, such as checkpoint inhibitors and ADCs. Checkpoint inhibitors help the immune system attack cancer cells, while ADCs (antibody-drug conjugates) deliver drugs directly to tumor cells.
Fewer side effects
AVC Boosters can treat many types of cancer, according to Arthur Lahr, CEO of Avidicure. They trigger a strong immune response only in the tumor, with fewer side effects.
First product targets lung cancer
The first product, AVC-S-101, targets the TROP2 protein. It is being developed for non-small cell lung cancer and other types of cancer.
A highly experienced team
Avidicure's management team has extensive experience. The founders previously worked at successful biotech companies such as Crucell, Ablynx, and Kiadis. The management team consists of Arthur Lahr (CEO), Dirk De Naeyer (COO), Robert Friesen (CSO), and Govert Schouten (CBO).
